Researchers at Atlantic Health System Have Reported New Data on Bladder Cancer [Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With Ugn-102 +/- Transurethral Resection of Bladder Tumor Compared To Transurethral...].

The article details a study comparing UGN-102, an intravesical chemoablation therapy, with transurethral resection of bladder tumor (TURBT) alone for treating low-grade intermediate-risk nonmuscle-invasive bladder cancer. Topics discussed include the trial's design, efficacy and safety results, and the adverse events associated with UGN-102.